MA31997B1 - Nouveaux derives de l'insuline presentant un profil d'action extremement retarde - Google Patents
Nouveaux derives de l'insuline presentant un profil d'action extremement retardeInfo
- Publication number
- MA31997B1 MA31997B1 MA32984A MA32984A MA31997B1 MA 31997 B1 MA31997 B1 MA 31997B1 MA 32984 A MA32984 A MA 32984A MA 32984 A MA32984 A MA 32984A MA 31997 B1 MA31997 B1 MA 31997B1
- Authority
- MA
- Morocco
- Prior art keywords
- insulin derivatives
- delayed action
- action profile
- novel insulin
- extremely delayed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne de nouveaux analogues d'insuline à profil temporel/d'action basal, caractérisés par une addition et/ou une substitution de radicaux aminoacide chargés négativement et positivement, et par une amidation du groupe carboxy c-terminal de la chaîne b, et de l'histidine en position 8 de la chaîne a de l'insuline. L'invention concerne également la fabrication et l'utilisation de ces analogues d'insuline.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008003566A DE102008003566A1 (de) | 2008-01-09 | 2008-01-09 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
US4466208P | 2008-04-14 | 2008-04-14 | |
DE200810025007 DE102008025007A1 (de) | 2008-05-24 | 2008-05-24 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
PCT/EP2009/000018 WO2009087082A2 (fr) | 2008-01-09 | 2009-01-06 | Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31997B1 true MA31997B1 (fr) | 2011-01-03 |
Family
ID=40473425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32984A MA31997B1 (fr) | 2008-01-09 | 2010-07-05 | Nouveaux derives de l'insuline presentant un profil d'action extremement retarde |
Country Status (21)
Country | Link |
---|---|
US (1) | US8633156B2 (fr) |
EP (1) | EP2229406B1 (fr) |
JP (1) | JP5695909B2 (fr) |
KR (1) | KR20100111683A (fr) |
CN (1) | CN101970476B (fr) |
AR (1) | AR070119A1 (fr) |
AU (1) | AU2009203810B2 (fr) |
BR (1) | BRPI0907119A2 (fr) |
CA (1) | CA2711752A1 (fr) |
CL (1) | CL2009000018A1 (fr) |
CO (1) | CO6290770A2 (fr) |
HK (1) | HK1148542A1 (fr) |
IL (1) | IL206843A0 (fr) |
MA (1) | MA31997B1 (fr) |
NZ (1) | NZ586589A (fr) |
PA (1) | PA8811501A1 (fr) |
PE (1) | PE20091305A1 (fr) |
TW (1) | TWI433681B (fr) |
UY (1) | UY31597A1 (fr) |
WO (1) | WO2009087082A2 (fr) |
ZA (1) | ZA201003927B (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005046113A1 (de) * | 2005-09-27 | 2007-03-29 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen |
EP2229407B1 (fr) | 2008-01-09 | 2016-11-16 | Sanofi-Aventis Deutschland GmbH | Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé |
KR101939557B1 (ko) | 2008-10-17 | 2019-01-17 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 glp-1 효능제의 병용물 |
WO2010070251A1 (fr) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Analogues du glucagon |
CA2747155A1 (fr) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Analogues du glucagon |
BRPI0823376A2 (pt) | 2008-12-15 | 2015-06-16 | Zealand Pharma As | Análagos de glucagon |
JP5635532B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
CN107308442B (zh) | 2009-11-13 | 2022-10-18 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物 |
PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
CA2802897A1 (fr) | 2010-06-24 | 2011-12-29 | Zealand Pharma A/S | Analogues de glucagon |
MX2012014247A (es) | 2010-06-24 | 2013-01-18 | Boehringer Ingelheim Int | Terapia para la diabetes. |
LT2611458T (lt) | 2010-08-30 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Ave0010 panaudojimas gaminant vaistą, skirtą 2 tipo cukrinio diabeto gydymui |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
MX2013008005A (es) | 2011-01-20 | 2013-08-21 | Zealand Pharma As | Combinacion de analogos de glucagon acilados con analogos de insulina. |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
MX370264B (es) | 2011-08-29 | 2019-12-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
TR201815338T4 (tr) | 2012-05-03 | 2018-11-21 | Zealand Pharma As | Gıp-glp-1 dual agonist bileşikleri ve yöntemler. |
MY170671A (en) | 2012-07-23 | 2019-08-26 | Zealand Pharma As | Glucagon analogues |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
HUE039616T2 (hu) | 2013-10-17 | 2019-01-28 | Zealand Pharma As | Acilezett glükagon analógok |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
JP2017503474A (ja) | 2013-11-06 | 2017-02-02 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン−glp−1−gipトリプルアゴニスト化合物 |
JP6735674B2 (ja) | 2014-01-09 | 2020-08-05 | サノフイSanofi | インスリンアスパルトの安定化された医薬製剤 |
EP3091995B1 (fr) | 2014-01-09 | 2024-03-20 | Sanofi | Formulations pharmaceutiques stabilisées d'insuline aspart |
BR112016013832A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico |
EP3098235A4 (fr) * | 2014-01-20 | 2017-10-18 | Hanmi Pharm. Co., Ltd. | Insuline à action prolongée et utilisation associée |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
BR112017008659A2 (pt) | 2014-10-29 | 2018-01-30 | Zealand Pharma As | ?métodos e compostos de agonista de gip? |
SI3229828T1 (sl) | 2014-12-12 | 2023-06-30 | Sanofi-Aventis Deutschland Gmbh | Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
BR112019005637A2 (pt) | 2016-09-23 | 2019-07-30 | Hanmi Pharm Ind Co Ltd | análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso |
US11752216B2 (en) | 2017-03-23 | 2023-09-12 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
CN110615836B (zh) * | 2018-06-20 | 2022-09-13 | 鲁南制药集团股份有限公司 | 一种利拉鲁肽的固相合成方法 |
CN115702880B (zh) * | 2021-08-12 | 2023-11-03 | 山东新时代药业有限公司 | 一种重组甘精胰岛素注射液及其制备工艺 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK347086D0 (da) * | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
DK113585D0 (da) | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
US5008241A (en) * | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
AU612141B2 (en) | 1987-02-25 | 1991-07-04 | Novo Nordisk A/S | Novel insulin derivatives |
DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
US5225323A (en) * | 1988-11-21 | 1993-07-06 | Baylor College Of Medicine | Human high-affinity neurotransmitter uptake system |
DK134189D0 (da) * | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
IL95495A (en) | 1989-08-29 | 1996-10-16 | Hoechst Ag | Fusion proteins their preparation and use |
DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
DE4405388A1 (de) | 1994-02-19 | 1995-08-24 | Hoechst Ag | Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen |
IL118127A0 (en) | 1995-05-05 | 1996-09-12 | Lilly Co Eli | Single chain insulin with high bioactivity |
CA2468374C (fr) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Derives de glp-1 |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
BR9813111A (pt) | 1997-10-24 | 2000-08-15 | Lilly Co Eli | Composições de insulina insolúveis |
US6444641B1 (en) * | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
JP2002509081A (ja) | 1998-03-12 | 2002-03-26 | バイオポア アイエヌシー. | 精子−卵結合に関与する分子の受精前の作用の増強 |
EP1076066A1 (fr) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides abaissant le taux de glucose sanguin |
DE19947456A1 (de) | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
DE10108212A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
DE10108211A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen |
JP4855640B2 (ja) * | 2001-04-02 | 2012-01-18 | ノヴォ ノルディスク アー/エス | インシュリン前駆体及びその調製方法 |
SK2432004A3 (sk) * | 2001-12-20 | 2005-04-01 | Eli Lilly And Company | Inzulínová zlúčenina s protrahovaným účinkom |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
CA2490564A1 (fr) | 2002-07-04 | 2004-01-15 | Zealand Pharma A/S | Glp-1 et methodes de traitement du diabete |
MXPA05003335A (es) * | 2002-10-02 | 2005-07-05 | Zealand Pharma As | Compuestos de exendina-4 estabilizados. |
CN1780854A (zh) * | 2003-04-29 | 2006-05-31 | 伊莱利利公司 | 具有延长时间作用的胰岛素类似物 |
AU2004234345A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
US7638299B2 (en) * | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
JP2008513384A (ja) | 2004-09-17 | 2008-05-01 | ノボ ノルディスク アクティーゼルスカブ | インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物 |
DE102004058306A1 (de) | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden |
MX2008003362A (es) | 2005-09-14 | 2008-03-25 | Sanofi Aventis Deutschland | Escision de precursores de insulinas mediante una variante de tripsina. |
WO2007081824A2 (fr) * | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Protéines résistantes à la fibrillation |
EP1972149B1 (fr) | 2006-01-10 | 2017-12-13 | Thomson Licensing DTV | Procedes et appareil utilises pour des mises en oeuvre paralleles d'un codage 4:4:4 |
EP2229407B1 (fr) | 2008-01-09 | 2016-11-16 | Sanofi-Aventis Deutschland GmbH | Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé |
-
2009
- 2009-01-06 EP EP09700949.2A patent/EP2229406B1/fr active Active
- 2009-01-06 NZ NZ586589A patent/NZ586589A/en not_active IP Right Cessation
- 2009-01-06 CN CN200980101942.6A patent/CN101970476B/zh not_active Expired - Fee Related
- 2009-01-06 AU AU2009203810A patent/AU2009203810B2/en not_active Ceased
- 2009-01-06 BR BRPI0907119-9A patent/BRPI0907119A2/pt not_active Application Discontinuation
- 2009-01-06 KR KR1020107014964A patent/KR20100111683A/ko not_active Application Discontinuation
- 2009-01-06 JP JP2010541744A patent/JP5695909B2/ja not_active Expired - Fee Related
- 2009-01-06 CA CA2711752A patent/CA2711752A1/fr not_active Abandoned
- 2009-01-06 WO PCT/EP2009/000018 patent/WO2009087082A2/fr active Application Filing
- 2009-01-07 UY UY031597A patent/UY31597A1/es not_active Application Discontinuation
- 2009-01-07 AR ARP090100036A patent/AR070119A1/es unknown
- 2009-01-07 TW TW098100283A patent/TWI433681B/zh not_active IP Right Cessation
- 2009-01-07 PE PE2009000010A patent/PE20091305A1/es not_active Application Discontinuation
- 2009-01-07 CL CL2009000018A patent/CL2009000018A1/es unknown
- 2009-01-07 PA PA20098811501A patent/PA8811501A1/es unknown
-
2010
- 2010-06-02 ZA ZA2010/03927A patent/ZA201003927B/en unknown
- 2010-06-22 US US12/820,727 patent/US8633156B2/en not_active Expired - Fee Related
- 2010-06-25 CO CO10076884A patent/CO6290770A2/es not_active Application Discontinuation
- 2010-07-05 MA MA32984A patent/MA31997B1/fr unknown
- 2010-07-06 IL IL206843A patent/IL206843A0/en unknown
-
2011
- 2011-03-17 HK HK11102681.7A patent/HK1148542A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2009203810A1 (en) | 2009-07-16 |
WO2009087082A3 (fr) | 2009-09-24 |
NZ586589A (en) | 2012-04-27 |
BRPI0907119A2 (pt) | 2015-07-14 |
PA8811501A1 (es) | 2009-09-17 |
US20110173722A1 (en) | 2011-07-14 |
EP2229406A2 (fr) | 2010-09-22 |
UY31597A1 (es) | 2009-08-31 |
TWI433681B (zh) | 2014-04-11 |
EP2229406B1 (fr) | 2015-04-22 |
WO2009087082A2 (fr) | 2009-07-16 |
CA2711752A1 (fr) | 2009-07-16 |
CN101970476B (zh) | 2014-08-27 |
PE20091305A1 (es) | 2009-09-26 |
CL2009000018A1 (es) | 2009-06-05 |
CO6290770A2 (es) | 2011-06-20 |
ZA201003927B (en) | 2011-04-28 |
US8633156B2 (en) | 2014-01-21 |
CN101970476A (zh) | 2011-02-09 |
KR20100111683A (ko) | 2010-10-15 |
AU2009203810B2 (en) | 2013-07-25 |
AR070119A1 (es) | 2010-03-17 |
IL206843A0 (en) | 2010-12-30 |
JP5695909B2 (ja) | 2015-04-08 |
HK1148542A1 (en) | 2011-09-09 |
JP2011509269A (ja) | 2011-03-24 |
TW200942257A (en) | 2009-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31997B1 (fr) | Nouveaux derives de l'insuline presentant un profil d'action extremement retarde | |
TN2010000298A1 (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
UA103015C2 (ru) | Новые производные инсулина с чрезвычайно замедленным профилем время/действие | |
NZ601374A (en) | Stabilized antibody-containing liquid formulations | |
BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
EA201391756A1 (ru) | Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами | |
MY192981A (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
EA201690623A1 (ru) | Простациклиновые соединения, композиции и способы их использования | |
BR112012029904A2 (pt) | métodos de purificação de polipeptídeos | |
WO2009155555A3 (fr) | Mise à jour de définitions de logiciel malveillant en continu | |
CY1110397T1 (el) | Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης | |
EA201491155A1 (ru) | Новые мутантные про-нрф и их применение для получения бета-нрф | |
BRPI0814971A8 (pt) | Proteína | |
EA201201608A1 (ru) | Солнцезащитная композиция | |
BR112012011467A2 (pt) | forma glicosilada de análogo ao glp-1 antigênico. | |
BR112012004697A2 (pt) | purificação melhorada de proteína através de uma eluição da proteína a modificada. | |
EA201600088A1 (ru) | Парентеральное введение тапентадола | |
MX2013008699A (es) | Compuestos para reducir la produccion de beta-amiloide. | |
EA201491225A1 (ru) | Шина, содержащая композицию, по существу, не включающую гуанидиновое производное и содержащую первичный амин | |
UA114592C2 (uk) | Пептид nd2 та спосіб лікування неврологічного захворювання | |
EP2593546A4 (fr) | Purification par affinité d'arn dans des conditions d'origine sur la base de l'interaction lambda boîteb/n peptide | |
IN2014CN02399A (fr) | ||
EP3956355A4 (fr) | Stabilisation d'analogues d'insuline prandiale ou basale par un pont diséléniure interne | |
EA201590431A1 (ru) | Пшеница с новыми аллелями rht-b1 | |
DE602007006493D1 (de) | Peptide mit proliferationshemmender wirkung |